OncLive TV

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses the rationale behind the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the future of treatment for patients with ovarian cancer.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses duration of checkpoint inhibitor therapy in patients with melanoma.

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.

Leslie J. Kohman, MD, FACS, Distinguished Service Professor of Surgery, Upstate Medical University, Upstate Cancer Center, discusses the results of the NELSON trial of screening in lung cancer.

Alexander E. Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the combination of tepotinib and gefitinib (Iressa) in patients with MET-positive EGFR-mutant non–small cell lung cancer (NSCLC).

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the benefit of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the treatment of patients with HER2-driven gastric cancer.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with diffuse large B-cell lymphoma.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the rationale for radiotherapy in the treatment of newly-diagnosed metastatic prostate cancer.

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Lawrence E. Feldman, MD, medical oncologist, University of Illinois Cancer Center, discusses the future of durvalumab (Imfinzi) and tremelimumab in non–small cell lung cancer (NSCLC).

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Ulrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.

Thomas Powles MBBS, MRCP, MD, professor of Genitourinary Oncology, lead, Solid Tumour Research, Barts Cancer Institute, director, Barts Cancer Centre, discusses biomarkers for immunotherapy in bladder cancer.

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, discusses the impact of the APHINITY trial on the treatment of patients with HER2-positive breast cancer.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses biomarkers in renal cell carcinoma.

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the future impact of biosimilars in oncology.

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses real-world results with regorafenib (Stivarga) in the treatment of patients with metastatic colorectal cancer (mCRC).

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.

Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.

Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the next steps with cemiplimab (Libtayo) in the treatment landscape of cervical cancer.

Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses ruxolitinib (Jakafi) failure in patients with myelofibrosis (MF).

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, addresses issues in the diagnosis of localized prostate cancer.

Mohammed J. Rahman, MD, oncologist, University of Pittsburgh Medical Center, discusses his understanding of the role of biosimilars in oncology.

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the frontline treatment of ALK-positive non–small cell lung cancer (NSCLC).